Parnassus Investments LLC Has $85.19 Million Stake in CME Group Inc. (NASDAQ:CME)

Parnassus Investments LLC lowered its stake in CME Group Inc. (NASDAQ:CMEFree Report) by 83.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 366,827 shares of the financial services provider’s stock after selling 1,890,660 shares during the period. Parnassus Investments LLC owned approximately 0.10% of CME Group worth $85,188,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Avidian Wealth Enterprises LLC raised its holdings in CME Group by 2.6% in the 4th quarter. Avidian Wealth Enterprises LLC now owns 1,769 shares of the financial services provider’s stock worth $411,000 after acquiring an additional 45 shares during the period. TFC Financial Management Inc. increased its stake in shares of CME Group by 8.4% in the fourth quarter. TFC Financial Management Inc. now owns 592 shares of the financial services provider’s stock worth $137,000 after purchasing an additional 46 shares during the period. Waldron Private Wealth LLC lifted its position in shares of CME Group by 2.0% during the 4th quarter. Waldron Private Wealth LLC now owns 2,362 shares of the financial services provider’s stock worth $549,000 after purchasing an additional 47 shares during the last quarter. Venturi Wealth Management LLC lifted its position in shares of CME Group by 12.1% during the 4th quarter. Venturi Wealth Management LLC now owns 437 shares of the financial services provider’s stock worth $101,000 after purchasing an additional 47 shares during the last quarter. Finally, First Affirmative Financial Network boosted its stake in CME Group by 2.3% during the 4th quarter. First Affirmative Financial Network now owns 2,141 shares of the financial services provider’s stock valued at $497,000 after purchasing an additional 49 shares during the period. Institutional investors own 87.75% of the company’s stock.

Insider Transactions at CME Group

In other news, insider Julie Winkler sold 11,592 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $249.17, for a total transaction of $2,888,378.64. Following the sale, the insider now owns 21,885 shares in the company, valued at approximately $5,453,085.45. This represents a 34.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Hilda Harris Piell sold 3,984 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $250.47, for a total value of $997,872.48. Following the completion of the sale, the insider now owns 27,046 shares of the company’s stock, valued at approximately $6,774,211.62. This trade represents a 12.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,076 shares of company stock valued at $4,271,496 in the last three months. 0.30% of the stock is owned by corporate insiders.

CME Group Stock Performance

Shares of NASDAQ:CME opened at $259.84 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.02. The business’s fifty day moving average price is $242.28 and its two-hundred day moving average price is $231.97. CME Group Inc. has a fifty-two week low of $190.70 and a fifty-two week high of $263.65. The stock has a market capitalization of $93.64 billion, a price-to-earnings ratio of 26.87, a price-to-earnings-growth ratio of 6.76 and a beta of 0.53.

CME Group (NASDAQ:CMEGet Free Report) last announced its earnings results on Wednesday, February 12th. The financial services provider reported $2.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.46 by $0.06. CME Group had a net margin of 57.52% and a return on equity of 13.62%. As a group, analysts predict that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group declared that its board has authorized a stock repurchase program on Thursday, December 5th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the financial services provider to buy up to 3.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

CME Group Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 26th. Stockholders of record on Friday, March 7th will be paid a $1.25 dividend. The ex-dividend date of this dividend is Friday, March 7th. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.92%. This is a boost from CME Group’s previous quarterly dividend of $1.15. CME Group’s payout ratio is 51.71%.

Analyst Ratings Changes

Several research analysts have commented on the company. Barclays lifted their price target on CME Group from $257.00 to $263.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Morgan Stanley upped their target price on shares of CME Group from $256.00 to $263.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 19th. Citigroup downgraded shares of CME Group from a “buy” rating to a “neutral” rating and reduced their price target for the company from $255.00 to $250.00 in a report on Monday, January 6th. Oppenheimer boosted their price objective on shares of CME Group from $258.00 to $269.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Finally, Raymond James upgraded shares of CME Group from a “market perform” rating to an “outperform” rating and set a $287.00 target price for the company in a research note on Monday. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, CME Group currently has an average rating of “Hold” and a consensus target price of $238.93.

Read Our Latest Analysis on CME Group

CME Group Company Profile

(Free Report)

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Read More

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.